Skip to main content



Pavan Khanna, MD, discusses the evolution of Y-90 for the treatment of HCC and reviews the LEGACY and DOSISPHERE trials, which highlight how TheraSphere™ is progressing Y-90 therapy towards more advanced dosimetry techniques and personalization.
Earlier this year, the Busch Clinic added Profound Medical’s TULSA system to its treatment options. TULSA, also called “inside-out” ablation, uses a unique cooling system to provide thermal protection of important anatomy. 
Dr Constantinos Sofocleous discusses the latest literature focused on liver metastatic disease.
Raul N. Uppot, MD, Interventional Radiologist from Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts, discusses the evolving role of hepatic ablation.
Osman Ahmed, MD, FCIRSE, discusses the recently published LEGACY Study, which confirmed Boston Scientific’s TheraSphere™ as a neoadjuvant or standalone therapy in treating HCC.
Back to Top